In a single-arm feasibility study, an allogeneic HER2+ GM-CSF-secreting BC vaccine was given with low-dose cyclophosphamide and weekly trastuzumab in 20 patients with HER2+ mBC (65). The gene discussed is CSF2; the disease is breast cancer.